CVX Carvolix SA
Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILOT Software, a robotic platform for transcatheter aortic valve implantation; TAVIPILOT Robot, mitral valve repair and replacement solutions; MITRAPILOT, a biomimetic transcatheter mitral valve; and Artedrone, an implantable artificial urinary sphincter. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.…
Industry Peers
Medical DevicesKey Statistics
About Carvolix (EPA: CVX)
›
Carvolix (EPA: CVX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 102 employees.
The shares were at 4.520 EUR on 19 November 2026, up 197.4% over 52 weeks. Its 52-week range is 1.330 EUR to 7.560 EUR: the price is 40.2% below the high and 239.8% above the low.
Its market capitalisation is 281.28M EUR.
Carvolix reports return on equity of -48.7% and revenue up 119.6% year over year.
Its debt exceeds its cash by 12.46M EUR, a debt-to-equity ratio of 0.54. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 8.775 EUR is 94.1% above the current price.